Dr. Kathy L. Baglan, MD

Dr. Baglan practices at Mercy Hospital St. Louis in Saint Louis, Missouri, part of Mercy.

Dr. Baglan's NPI, 1538122163, was assigned on April 6, 2006. Dr. Baglan graduated from WashU Medicine in 1997. Dr. Baglan holds Missouri license 2001031798.

Dr. Baglan's primary practice is Mercy Hospital St. Louis, at 615 New Ballas Road, Saint Louis, MO 63141 in St. Louis County. The practice phone is (314) 251-6000.

Dr. Baglan's primary practice is Mercy Hospital St. Louis in Saint Louis, Missouri, part of Mercy. Dr. Baglan is also affiliated with Mercy Hospital South. The medical group on file is West County Radiological Group. Dmand AI also links Dr. Baglan to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Baglan practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Baglan's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Baglan is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Baglan's licenses on file in 4 states: Missouri, Illinois, Kansas and Michigan.

Dmand AI lists bone cancer radiation, breast cancer radiation, lung cancer radiation, lymphoma radiation and prostate cancer radiation among the conditions Dr. Baglan treats.

CMS data shows 1,223 Medicare services from Dr. Baglan across 16 procedure codes in 2024, for 222 Medicare patients. Medicare paid $79,024 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 222 Medicare patients who saw Dr. Baglan in 2024. The largest group is 65 to 74, with 113 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Baglan's median patient age at 73, with 41% women.

In 2024, Dr. Baglan wrote 277 Medicare Part D claims for 93 patients. 96% of them were for generic drugs. CMS names the drug for 218 of them, across 2 drugs with 11 or more claims each, at $1,463 in total drug cost. In 2023, CMS named 207 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Baglan for performance year 2024, reported as part of a group. Dr. Baglan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Baglan as offering telehealth.

Dmand AI links 5 papers to Dr. Baglan in 2018. The most frequent topics are Dose-Response Relationship, Radiation. Dr. Baglan has published most often in Int J Radiat Oncol Biol Phys. Dr. Baglan's most frequent co-authors are Alvaro A. Martinez, MD, Robert C. Frazier, MD and Cristiane Takita, MD.

Dmand AI links Dr. Baglan to 2 clinical trials. Conditions studied include Cholangiocarcinoma, Pancreatic Neoplasms and Carcinoma, Hepatocellular. Mercy Research sponsors the most, 2.

CMS Open Payments shows 46 general payments to Dr. Baglan from 18 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Myriad Genetic Laboratories, Inc. paid the most, $603.

Dr. Baglan graduated from WashU Medicine in 1997.

Dr. Baglan is in network with 17 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.